platoseedplatoseed
Our drugs engage the immune system to fight tumors
We are developing cancer therapeutics using small molecules that inhibit immune suppression. Our drugs engage the immune system to aggressively fight tumors. Our therapeutic portfolio addresses a range of solid tumors, starting with mesothelioma.
Eris Biotech develops first-in-class small-molecule inhibitors that reawaken the immune system to fight cancer. Their orally administered drug aims to block tumor immune evasion and engage immunity to halt cancer progression.
The company has identified a pathway responsible for immune evasion in cancer and developed an oral, small-molecule inhibitor that does not rely on a protein target. The drug is designed to safely reawaken the immune system to recognize and attack tumors, enabling broader patient applicability.
Who it’s for: oncology researchers, pharmaceutical developers, mid-to-late stage biotechs, and cancer centers seeking immunotherapy alternatives
no explicit funding or hiring information provided in the text
PhD in Immunology from Dartmouth College. Engineered many novel cancer immunotherapies. We build cancer drugs that reawaken the immune system to fight cancer for you. No tox, no side effects, and most importantly -- no cancer.
PhD in microbiology and molecular biology with an emphasis in cancer immunology, working on developing drugs that reawaken the immune system to fight cancer. First-generation immigrant from Peru. Mom of two boys.
Tumors turn OFF the immune system. Our drugs turn the immune system ON to kill cancer.
Eris Biotech develops small-molecule drugs that prevent tumors from releasing immune-suppressing vesicles, thereby restoring immune surveillance and enabling the body's immune system to fight cancer. They announce a first-in-class approach starting with mesothelioma, aiming to awaken the immune system rather than directly killing cancer cells.
From the original launch (Feb 2024) — may be outdated.
Adventris makes cancer vaccines
Enabling Tissue Targeting of Therapies
